menu
    • menu
    [{"orgOrder":0,"company":"BioTheryX","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"BTX-A51","moa":"CK1-alpha","graph1":"Oncology","graph2":"Phase I","graph3":"BioTheryX","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioTheryX \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BioTheryX \/ Inapplicable"},{"orgOrder":0,"company":"BioTheryX","sponsor":"MSD Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Series D Financing","leadProduct":"BTX-A51","moa":"CK1-alpha","graph1":"Oncology","graph2":"Phase I","graph3":"BioTheryX","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioTheryX \/ MSD Partners","highestDevelopmentStatusID":"6","companyTruncated":"BioTheryX \/ MSD Partners"},{"orgOrder":0,"company":"Edgewood Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"BTX-A51","moa":"CK1-alpha","graph1":"Oncology","graph2":"Phase II","graph3":"Edgewood Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Edgewood Oncology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Edgewood Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Edgewood Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"BTX-A51","moa":"CK1-alpha","graph1":"Oncology","graph2":"Phase II","graph3":"Edgewood Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Edgewood Oncology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Edgewood Oncology \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals for (1R,4r)-N1-(5-chloro-4-(5-(cyclopropylmethyl)-1-methyl-1H-pyrazol-4-yl)pyrimidin-2-yl)cyclohexane-1,4-diamine

    Menu

    (1R,4r)-N1-(5-chloro-4-(5-(cyclopropylmethyl)-1-methyl-1H-pyrazol-4-yl)pyrimidin-2-yl)cyclohexane-1,4-diamine

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Edgewood Oncology

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            Edgewood Oncology

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BTX-A51

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Edgewood Oncology Reports Efficacy Data from BTX-A51 Study in Liposarcoma

                            Details : BTX-A51 is a first-in-class small molecule inhibiting CK1α, CDK7, and CDK9, currently being evaluated for treating liposarcoma.

                            Product Name : BTX-A51

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            July 04, 2024

                            Lead Product(s) : BTX-A51

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Edgewood Oncology

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            Edgewood Oncology

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BTX-A51

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Edgewood Doses First Patients In Phase 2a Study Of BTX-A51 For Breast Cancer

                            Details : BTX-A51 is a first-in-class, small molecule, multi-selective kinase inhibitor of casein kinase 1 alpha as well as the transcriptional regulators CDK7 and CDK9. It is being evaluated for liposarcoma.

                            Product Name : BTX-A51

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            May 21, 2024

                            Lead Product(s) : BTX-A51

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            BioTheryX

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            BioTheryX

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BTX-A51

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : MSD Partners

                            Deal Size : $35.0 million

                            Deal Type : Series D Financing

                            DEALS_DEV arrow-down

                            BioTheryX Announces $35 Million Series D Financing

                            Details : Proceeds from the financing will be used to accelerate the timeline of the BTX-A51 Phase 1 clinical trial through, continue IND-enabling studies for therapeutic candidates utilizing both PHMs™ and PHM®-based PROTACs and general corporate purposes.

                            Product Name : BTX-A51

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            July 28, 2020

                            Lead Product(s) : BTX-A51

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : MSD Partners

                            Deal Size : $35.0 million

                            Deal Type : Series D Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            BioTheryX

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            BioTheryX

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BTX-A51

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            BioTheryX Announces the Initiation of Patient Dosing in a First-in-Man Phase 1 Clinical Trial of BTX-A51, a Mu...

                            Details : Study is evaluating the safety/tolerability of BTX-A51 in patients with relapsed/refractory acute myeloid leukemia (AML), as well as high risk myelodysplastic syndrome patients.

                            Product Name : BTX-A51

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            January 16, 2020

                            Lead Product(s) : BTX-A51

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth